Project Grant R42AI131792

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $300,000 to support the preclinical development of occidiofungin, a novel antifungal compound, for the treatment of oral and dermal candidiasis. The key objectives are to establish an effective formulation, conduct toxicological and stability studies, and prepare an Investigational New Drug (IND) application...

This $300,000 Project Grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under CFDA 93.855 Allergy and Infectious Diseases Research program aims to develop an anti-Candida peptide vaccine. The goal is to create a vaccine that can be used alone or as an adjunct to antifungal drugs to reduce fungal burden and morbidity due to life-threatening disseminated candidiasis, a common bloodstream infection in hospitalized patients. The project will utilize a novel...

This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides funding to Osel, Inc., a biotechnology company based in Mountain View, California, to develop a novel antimicrobial approach to treat chemoradiation-resistant cervical cancer. The key products and services to be delivered under this $295,881 award, which runs from May 2025 to April 2026, are: Synthesis and characterization of a selective bacteriocin inhibitor, GASK7B, that can...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (CFDA 93.855 - Allergy and Infectious Diseases Research) provides $112,539 to The University of Texas at San Antonio (UTSA) to repurpose existing FDA-approved drugs as potential novel antifungal treatments for coccidioidomycosis, also known as Valley Fever. The research aims to identify synergistic drug combinations that can enhance efficacy, reduce toxicity, and mitigate resistance risks compared to...

This Project Grant award from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) provides $349,808 to Oncurie Inc. to continue development of a novel targeted radiopharmaceutical for imaging and potential therapy of ovarian cancer. The compound leverages the folate receptor overexpression in ovarian tumors to enable precision imaging, with future plans to incorporate cytotoxic radionuclides for targeted therapy. During the Phase I award period from Sep 2024...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, will support research to accelerate the discovery of novel antifungal peptides. The $642,775 award to the University of California, Davis will fund a multi-step, high-throughput screening platform leveraging one-bead one-compound (OBOC) combinatorial technology. The goal is to rapidly identify and optimize...

This Project Grant award from the National Cancer Institute's Cancer Treatment Research program (CFDA 93.395) provides $367,472 to support the development of Gynion, LLC's ClaraBlex gel for the ablative treatment of cervical intraepithelial neoplasia (CIN), a precancerous condition caused by human papillomavirus (HPV) infection. The ClaraBlex gel, formulated with trichloroacetic acid, is designed to provide a simple, effective, and affordable point-of-care treatment that can be readily...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $112,077 to The Ohio State University to develop novel bacteriophage-based therapies to combat Pseudomonas aeruginosa and Candida species dual-species biofilms. The key objectives are to: 1) develop combination treatments using antimicrobial peptides and bacteriophages, and 2) genetically engineer P. aeruginosa...

The Food and Drug Administration (FDA) awarded a $162,501 Cooperative Agreement under the FDA Research program (CFDA 93.103) to The Trustees of the University of Pennsylvania, doing business as Clinical Practices of the University of Pennsylvania, for a pilot study on veterinary antifungal use and resistance. The two-year project, beginning August 1, 2024, will assess veterinarians' knowledge, attitudes, and practices related to antifungal resistance, risk factors for fungal infections,...

This federal Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is providing $402,860 to the University of Cincinnati to develop a molecular toolbox for the fungal pathogen Pneumocystis jirovecii (PJ). The primary goal is to establish a transformation system using CRISPR/Cas9 gene editing and plasmid-mediated approaches to enable functional studies on the biology and pathogenesis of...